Publications

Malagise E, Keeling E, Knezovich N, Waybright L, Watto E, Caggiano AO, Ratnayaka A, Hamby ME (2022 May). Sigma-2 receptor modulators rescue POS trafficking deficits in RPE cell-based models of dry AMD. Poster presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); Denver, CO.

Izzo NJ, LaBarbera KM, Yuede CM, Waybright L, Yurko R, Sheline YI, Edwards HM, Gardiner WD, Blennow K, Zetterberg H, Hanson AB, Davis CS, Guttendorf RJ, Schneider LS, DeKosky S, Caggiano AO, Grundman M, Catalano SM, Cirrito JR, Hamby ME (2022 March). Experimental Therapeutic CT1812 Demonstrates Target Engagement in a Phase 1b Clinical Trial to Measure Displacement of Aβ Oligomers Into CSF. Poster presented at: AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases; Barcelona, Spain.

Seyfried N, Waybright L, Duong D, Malagise E, Pandey K, Williams C, Dammer E, Ping L, Blennow K, Zetterberg H, Lah J, Levey A, Ricciardi L, Caggiano AO, Hamby ME (March 2022). Proteomic Analysis of CSF in a Phase 2 Clinical Trial for AD to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812. Poster presented at: AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases; Barcelona, Spain. 

Colom-Cadena M, Tulloch J, Jackson RJ, Catterson JH, Rose J, Davies C, Hooley M, Anton-Fernandez A, Dunnett S, Tempelaar R, Tzioras M, Izzo NJ, Catalano SM, Smith C, Spires-Jones TL. TMEM97 increases in synapses and is a potential synaptic Aβ binding partner in human Alzheimer’s disease. bioRxiv 2021.02.01.428238; doi.org/10.1101/2021.02.01.428238

Rishton GM, Look GC, Ni Z-J, Zhang J, Wang Y, Huang Y, Wu X, Izzo NJ, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, Catalano SM. Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer’s Disease. ACS Med Chem Lett. 2021 Aug 9;12(9):1389-1395.

Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, Waybright L, Look G, Rishton G, Safferstein H, Hamby ME, Williams C, Sadlek K, Edwards HM, Davis CS, Grundman M, Schneider LS, DeKosky ST, Chelsky D, Pike I, Henstridge C, Blennow K, Zetterberg H, LeVine H, Spires-Jones TL, Cirrito JR Catalano SM. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer’s disease modification. Alzheimer’s Dement. 2021 Aug; 17(8):1365-1382

Limegrover CS, Yurko R, Izzo NJ, LaBarbera KM, Rehak C, Look G, Rishton G, Safferstein H, Catalano SM. Sigma‐2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain‐derived α‐synuclein. J Neurosci Res. 2021; 00: 1– 16.

Izzo NJ, Colom-Cadena M, Riad AA, Xu J, Singh M, Abate C, Cahill MA, Spires-Jones TL, Bowen WD, Mach RH, Catalano SM. Proceedings from the Fourth International Symposium on σ-2 Receptors: Role in Health and Disease. 7(6) ENEURO .0317-20.2020 1–7

Limegrover, CS, LeVine, H, III, Izzo, NJ, Yurko, R, Mozzoni, K, Rehak, C, Sadlek, K, Safferstein, H and Catalano, SM. Alzheimer’s Protection Effect of A673T Mutation May Be Driven by Lower Aβ Oligomer Binding Affinity. J Neurochem2020001– 15.  doi:10.1111/jnc.15212

Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, Fillit H, Harrison JE, Schneider LS, Scheltens P, de Haan W, Grundman M, van Dyck CH, Izzo NJ, Catalano SM and the Synaptic Health Endpoints Working Group. The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease. Alz Res Therapy 12, 21 (2020)

Grundman M, Morgan R, Lickliterd JD, Schneider LS, DeKosky S, Izzo NJ, Guttendorf R, Higgin M, Pribyli J, Mozzoni J, Safferstein H, Catalano SM. A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer’s disease. Alzheimers Dement (N Y). 2019 Jan 23; 5:20-26

Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, Rehak C, Yurko R, Look G, Rishton G, Safferstein H, Cruchaga C, Goate A, Cahill MA, Arancio O, Mach RH, Craven R, Head E, LeVine H 3rd, Spires-Jones TL, Catalano SM. Alzheimer’s therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity PLoS One. 2014 Nov 12; 9(11):e111899

Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, Wostein H, Walko T 3rd, Vaswani A, Wardius M, Syed Z, Ravenscroft J, Mozzoni K, Silky C, Rehak C, Yurko R, Finn P, Look G, Rishton G, Safferstein H, Miller M, Johanson C, Stopa E, Windisch M, Hutter-Paier B, Shamloo M, Arancio O, LeVine H 3rd, Catalano SM. Alzheimer’s therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits PLoS One. 2014 Nov 12; 9(11):e111898

Foundational Principles of Neuroscience: Genetic Basis of Alzheimer’s Disease: Synapse Loss Correlates to Cognitive Deficit: Monomers, Oligomers, Fibrils and Plaques – the Aβ Equilibrium: Aβ Accumulates and Self-Associates into Oligomers: Aβ Oligomers Bind to a Receptor Complex on Synapses: Bound Aβ Oligomers are Toxic to Synapses: Sigma-2 Receptor Complex Biology and Role in Disease: Biomarkers of Disease and Target Engagement:
AMD Rationale:
Scroll to Top

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.